argenx SE (ARGX) Stock

About argenx SE

argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.

argenx SE is headquartered in NL.

argenx SE (ARGX) stock trades at $862.93 with a market capitalization of $53.99B. The stock is valued at a price-to-earnings (P/E) ratio of 48.25, price-to-book of 7.22, price-to-sales of 15.85. Over the past 52 weeks the stock has ranged between $558.34 and $953.58, and currently trades 9.5% below its 52-week high.

On profitability, argenx SE generates a return on equity (ROE) of 16.82%, above the typical market average, return on capital employed of 11.76%, an operating margin of 25.64%, a net profit margin of 33.42%.

In its most recent fiscal year, argenx SE reported annual revenue of $4.2B, net profit of $1.3B, revenue has compounded at 151.8% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.01 — a conservative balance sheet with little leverage risk, a current ratio of 5.23, total assets of $8.7B, $3.5B in cash and equivalents.

ARGX has an average daily trading volume of 342,998 shares, a beta of -0.02 (less volatile than the overall market).

Official website: www.argenx.com